• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·China·Healthcare·688389.SS
Share

Shenzhen Lifotronic Technology Co., Ltd. Stocks

CN¥ 10.87Last Updated 14.07.2026

Issuer Rating

5/7
Performance

Favourable

Risk

Limited

Recommendation

Hold

Market Cap

CN¥ 664.61M

CN¥ 10.87
Key Takeaways

Risk factor

Fair trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Decent dividends

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Established in 2008 and headquartered in Shenzhen, China, Shenzhen Lifotronic Technology Co., Ltd. specializes in the design, production, and distribution of a wide range of medical devices throughout China, addressing both diagnostic and therapeutic requirements. Its extensive portfolio includes In Vitro Diagnostic (IVD) products, featuring sophisticated analytical instruments such as HPLC systems for hemoglobin and HbA1c measurements, automated ECL immunoassay analyzers, and hematology analyzers. The company also provides Point-of-Care Testing (POCT) solutions, including immunofluorescence analyzers, alongside molecular diagnostics equipment like automated nucleic acid purification systems and real-time PCR platforms. Additionally, Lifotronic offers rapid test kits for key infectious diseases such as COVID-19, malaria, dengue, and influenza A and B. In the therapeutic sector, the company delivers a diverse array of solutions. Respiratory and ICU products encompass video laryngoscopes, warmer units with disposable blankets, high-flow humidification systems, high-frequency chest wall oscillation devices, and intermittent pneumatic compression pumps. For wound care, offerings include negative pressure wound therapy, ultrasound-assisted wound debridement, and wound healing light therapy. Pain management is addressed through ESWT (Extracorporeal Shockwave Therapy) devices, specifically electromagnetic and extracorporeal shockwave systems. Furthermore, Lifotronic is active in medical and aesthetic laser technologies, providing intensive pulsed light systems, fractional CO2 laser systems, Q-switched Nd:YAG laser systems, and fiber laser hair removal systems.

Company Valuation

Fairly valued
4/7

Based on key historical and expected multiples, the stock is fairly valued relative to its peers. Specifically, the stock is fairly valued on P/E, neutral on EV/EBITDA, r

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

15.07.2026 07:30

Chinese AI developer DeepSeek has begun preparations for an IPO next year — Bloomberg

15.07.2026 03:24

Lucid's stock plummeted following news of a possible bankruptcy. At one point, it was down 57%.

15.07.2026 02:16

"The Prisoner's Dilemma": JPMorgan Warns of a Threat to Coinbase and Circle's Profits

15.07.2026 01:24

Inflation data pushed the indices higher. Software developers are under pressure again

15.07.2026 00:57

Biogen shares fell after disappointing data on its Alzheimer's drug

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026